Champions Oncology, Inc. (CSBR)
Automate Your Wheel Strategy on CSBR
With Tiblio's Option Bot, you can configure your own wheel strategy including CSBR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CSBR
- Rev/Share 4.2764
- Book/Share 0.3992
- PB 14.7052
- Debt/Equity 1.177
- CurrentRatio 0.9913
- ROIC 0.6277
- MktCap 81163903.0
- FreeCF/Share -0.0966
- PFCF -61.3484
- PE 12.5133
- Debt/Assets 0.2102
- DivYield 0
- ROE 6.5665
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CSBR | Craig Hallum | Hold | Buy | -- | $6 | Sept. 12, 2024 |
News
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge research, featuring innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing, as well as AI-driven models that utilize multi-omics datasets to predict patient outcomes.
Read More
About Champions Oncology, Inc. (CSBR)
- IPO Date 2007-02-02
- Website https://www.championsoncology.com
- Industry Biotechnology
- CEO Dr. Ronnie Morris M.D.
- Employees 210